Company: REVB
Filing Date: 2025-09-30
Form Type: S-3/A
Source: 0001193125-25-223617
Chunk: 1

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-09-30
Form: S-3/A
Chunk 1
---
eto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐ If this Form is a post-effective amendment filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, please check the following box. ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “Emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934:

| Large accelerated filer | ☐ | Accelerated filer         | ☐ |
| Non-accelerated filer   | ☒ | Smaller reporting company | ☒ |
|                         |   | Emerging growth company   | ☐ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒ The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

PRELIMINARY PROSPECTUS

<div align='center'>Revelation Biosciences, Inc.

13,065,000 Shares of Common Stock</div>

This prospectus relates to the resale, from time to time, of up to 13,065,000 shares of common stock, par value $0.001 per share, by the selling stockholders identified in this prospectus under “Selling Stockholders” (the “Selling Stockholders”) to be issued upon the exercise of common stock purchase warrants (the “Class I Common Stock Warrants”) pursuant to an inducement offer letter agreement the Company entered into with the Selling Stockholders on September 10, 2025 (the “Inducement Letter”). The Class I Common Stock W